Hemogenyx Pharmaceuticals plc

Detailed Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.